Metformin in Women With Type 2 Diabetes in Pregnancy Trial

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 500 participants.

Also called NCT01353391

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 500 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01353391
Other papers using this trial's data
  • Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial The lancet. Diabetes & endocrinology, 2020-10 DOI, PubMed 32946820 PubMed links an erratum for this paper. Erratum: PMID 33065062

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01353391. Randomized; quadruple masking; primary purpose treatment. Start 2011-05-25 (actual); primary completion 2019-06-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Metformin in Women With Type 2 Diabetes in Pregnancy Trial
Acronym
MiTy
Intervention (Drug)
Metformin
Intervention (Drug)
Placebo Comparator
Lead sponsor
Mount Sinai Hospital, Canada (class: other)
Collaborator
University Health Network, Toronto (class: other)
Collaborator
Sunnybrook Research Institute (class: other)
Collaborator
Canadian Institutes of Health Research (CIHR) (class: other government)

Record details

Record id
cardio:ct-nct01353391
Content hash
9d30be92cf2df92a035b9be8b3cd8bf604a8548946f4a24b326308c8855e9fd7